Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure by Hammadah, Muhammad et al.
Cleveland State University
EngagedScholarship@CSU
Mathematics Faculty Publications Mathematics Department
1-1-2016
Elevated Soluble Fms-Like Tyrosine Kinase-1 and
Placental-Like Growth Factor Levels Are
Associated With Development and Mortality Risk
in Heart Failure
Muhammad Hammadah
Heart and Vascular Institute
Vasiliki V. Georgiopoulou
Heart and Vascular Institute
Andreas P. Kalogeropoulos
Heart and Vascular Institute
Malory Weber
Heart and Vascular Institute
Xi Wang
Heart and Vascular Institute
See next page for additional authorsFollow this and additional works at: https://engagedscholarship.csuohio.edu/scimath_facpub
Part of the Mathematics Commons
How does access to this work benefit you? Let us know!
This Article is brought to you for free and open access by the Mathematics Department at EngagedScholarship@CSU. It has been accepted for
inclusion in Mathematics Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact
library.es@csuohio.edu.
Repository Citation
Hammadah, Muhammad; Georgiopoulou, Vasiliki V.; Kalogeropoulos, Andreas P.; Weber, Malory; Wang, Xi; Samara, Michael A.;
Wu, Yuping; Butler, Javed; and Tang, W.H. Wilson, "Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor
Levels Are Associated With Development and Mortality Risk in Heart Failure" (2016). Mathematics Faculty Publications. 186.
https://engagedscholarship.csuohio.edu/scimath_facpub/186
Authors
Muhammad Hammadah, Vasiliki V. Georgiopoulou, Andreas P. Kalogeropoulos, Malory Weber, Xi Wang,
Michael A. Samara, Yuping Wu, Javed Butler, and W.H. Wilson Tang
This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scimath_facpub/186
Placental-like growth factor (PlGF), a member of the vascu-lar endothelial growth factor (VEGF) family, and soluble 
Fms-like tyrosine kinase-1 (sFlt-1) are vascular biomarkers 
that were found to be involved in the preeclampsia process 
and peripartum cardiomyopathy.1 PlGF stimulates endothelial 
healing and recruitment of mononuclear bone marrow cells, 
and thus, it has a role in stimulating microvascular angiogen-
esis.2 In contrast, sFlt-1 plays a counter-regulatory role by 
sequestering and blocking circulating PlGF.3 Both markers 
were found to be elevated in heart failure (HF), and higher 
sFlt-1 has been associated with adverse clinical outcomes.4 
Furthermore, in animal models, antagonizing VEGF by beva-
cizumab has been associated with development of HF.5 These 
observations may imply that such vascular processes may be 
mechanistically linked to HF disease progression. Therefore, 
we aim to test the hypothesis that PlGF and sFlt-1 are associ-
ated with adverse outcomes in HF regardless of underlying 
reduced or preserved ejection fraction (EF), and in distinct 
but complementary animal HF models, that sFlt-1 generation 
occurs independent of cardiac insult.
Methods
Study Population
A total of 791 subjects with HF were enrolled from Cleveland Clinic 
GeneBank study, a large, prospective cohort study conducted between 
2001 and 2007 that established a well-characterized clinical reposi-
tory with clinical and longitudinal outcome data composed of consent-
ing subjects undergoing an elective diagnostic cardiac catheterization 
procedure. This analysis included 791 subjects with HF, out of 2000 
patients, without evidence of myocardial infarction (MI, cardiac tro-
ponin I <0.03 ng/mL) and with plasma samples available for analysis. 
The inclusion criteria included age older than 18 years, ability to un-
derstand and sign written informed consent to participate, and a diag-
nosis of HF with either reduced or preserved EF. Exclusion criteria 
included congenital heart disease, previous heart transplant, known 
cardiac infiltrative disease (eg, amyloidosis), previous other solid or-
gan transplantation, and end-stage HF requiring outpatient continuous 
inotrope infusion. Institutional review board approval was obtained, 
and informed consent was signed by all subjects before enrollment.
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Because difference between levels of vascular markers in HF 
population and normal population is unknown, we have also enrolled 
a group of 312 healthy young subjects to determine reference range 
of vascular biomarkers.
sFlt-1 and PlGF Measurement and Patient Groupings
After informed consent, all patients had collection of blood samples at 
baseline. Levels of sFlt-1 and PlGF were measured using investigation-
al immunoassays on the Architect ci8200 platform in a research core 
laboratory (Abbott Laboratories, Abbott Park, IL). B-type natriuretic 
peptide (BNP) levels were also measured in the same samples using 
the sample platform. Patients were grouped into those with high levels 
of vascular markers (≥cutoff) and low levels (<cutoff). An estimate of 
creatinine clearance was calculated using the Cockcroft–Gault equa-
tion. The presence of coronary artery disease was confirmed by luminal 
stenosis of at least 70% in any major coronary artery. Left ventricular 
EF was determined by the last best available data from clinical records 
(echocardiography, radionucleotide imaging, or ventriculogram during 
coronary angiography in order of preference). Adjudicated long-term 
survival was ascertained for all subjects after enrollment. Mortality 
data were collected through medical records review, information from 
family members, and Social Security Death Index query.
Animal Models of HF
The Cleveland Clinic Institutional Animal Care and Use Committee 
approved all animal studies. We assessed circulating sFlt-1 levels in 
2 well-established rodent HF models representing cardiac insults 
caused by acute MI (left anterior descending [LAD] coronary liga-
tion) and by pressure overload (transverse aortic constriction [TAC]), 
as previously described.6 For the LAD ligation model, the left atrium 
was retracted for visualization of the proximal LAD using a surgical 
microscope (Leica M500, Prescott’s Inc., Monument, CO) and the 
LAD coronary artery was ligated with 10-0 prolene suture. For the 
TAC model, midsternal incision was made to expose transverse aorta 
between truncus anonymous and the left carotid artery. With 6-0 silk 
suture, a ligature is tied around the transverse aorta against a 26-gauge 
needle. Both HF models were performed in 12-week male C57BL/6J 
mice, and plasma samples were collected by ventricular puncture at 
the time of euthanize after 4 weeks postoperatively from LAD mice 
(n=4) and TAC mice (n=4) and 8 weeks postoperatively from LAD 
mice (n=3) and TAC mice (n=6). Plasma sFlt-1 was assayed using a 
mouse assay (Quantikine ELISA, R&D Systems, Minneapolis, MN).
Statistical Analysis
The Student t test or Wilcoxon-rank sum test, for continuous variables, 
and χ2 test for categorical variables were used to examine differences 
between the groups. Survival and event rates were described with the 
Kaplan–Meier method. Cox proportional hazards regression was used to 
determine hazard ratios and 95% confidence intervals for 5-year survival. 
In multivariable models, we adjusted for traditional cardiac risk factors, 
including age, sex, race, log-transformed body mass index, diabetes 
mellitus, systolic blood pressure, low-density lipoprotein, high-density 
lipoprotein, calculated glomerular filtration rate, smoking, coronary ar-
tery disease and medications (angiotensin converting enzyme inhibitors, 
β-blockers), and log-transformed EF. Analyses were also repeated after 
adjustment for baseline log-transformed BNP and cardiac troponin I lev-
els. Receiver operator characteristic curve analyses with 5-fold cross-val-
idation were used to determine the optimal sFlt-1 and PlGF cutoffs. For a 
given cutoff, we used a Cox model to estimate mortality risk. The 5-fold 
cross-validation divides the data into 5 approximately equally sized por-
tions. A Cox model is trained on 4 parts of the data and then estimates 
the risk of mortality in the fifth part. This is repeated for each of the 5 
parts. We calculated the area under the curve with the estimated risk. 
This process is performed for a grid of sFlt-1 and PlGF cutoff values, 
ranging from 105.6 to 21 044 pg/mL with an increment of 1 pg/mL for 
sFlt-1 and ranging from 8.2 to 84.5 pg/mL with an increment of 0.5 pg/
mL for PlGF. The optimal cutoff is chosen to maximize area under the 
curve values. We also used logistic regression to assess factors associated 
with increased odds of having high levels of vascular markers (≥cutoffs).
Results
Baseline Patient Characteristics
Overall, a total of 791 patients with diagnosis of HF were 
included in this study. The baseline characteristics of the study 
population are presented in Table 1. Compared with the ref-
erence group of 312 healthy young subjects assessed by our 
laboratory (mean age, 42±14 years; male. 41%; smoking, 7%; 
Table I in the Data Supplement), and after adjustment for age, 
sex, race, diabetes mellitus, hypertension, hyperlipidemia and 
smoking, patients with HF had significantly higher levels of 
sFlt-1 [median of 382 (277–955) versus 249 (226–276) pg/mL, 
 adjusted P=0.005] and PlGF [median of 24 (20–29) versus 
15.5 (13.5–18) pg/mL, adjusted P<0.001; Figure 1].
Demographics Based on sFlt-1 Levels
Using area under the curve and 5-fold cross-validation as 
described above, cutoff of 280 pg/mL for sFlt-1 and 25 pg/mL 
for PlGF was found to maximize area under the curve for asso-
ciation with adverse outcomes. Table 1 showed demographics 
based on high/low sFlt-1 levels using these cutoffs. Patient 
with high sFlt-1 had significantly lower creatinine clearance 
as well as higher BNP levels. Using multivariate logistic 
regression analysis, we found decreased creatinine clearance 
as well as increased BNP levels to be independent predictors 
of high sFlt-1 and PlGF. Presence of coronary artery disease 
was also found to be an independent predictor of high PlGF.
sFlt-1 and PlGF and Long-Term Survival in HF 
Patients
After 5 years of follow-up, 228 (28.8%) of the patients reached 
the primary outcome (all-cause mortality). High levels of 
sFlt-1 and PlGF were significantly associated with higher rate 
of adverse outcomes (Table 2). After adjustment for coronary 
artery disease risk factors, medications, creatinine clearance, 
EF, BNP, and cardiac troponin I, high sFlt-1 but not PlGF 
remained an independent predictor of all-cause mortality with 
hazard ratio (95% confidence interval) of 1.47 (1.03–2.09); 
P=0.035 and 1.26 (0.94–1.71); P=0.12, respectively (Figure 2). 
Subgroup analysis showed sFlt-1 to be associated with adverse 
outcomes mainly in patients with EF >40% and patients with 
coronary artery disease. However, there was no significant 
interaction between sFlt-1 and EF. Similarly, no interaction 
was found between PlGF and EF. We validated these results 
on a group of 175 patients with predominantly, nonischemic 
HF with low EF (coronary artery disease, 39%; EF, 26±14%) 
enrolled from the Atlanta cardiomyopathy consortium (TACC) 
with a mean follow-up of 3.5±1 years. In this group of patients, 
only sFlt-1 but not PlGF showed significant association with 
increased mortality risk (Figure I in the Data Supplement).
sFlt-1 in Animal Models of HF
Giving the results of subgroup analyses, where sFlt-1 was 
mainly associated with adverse outcomes in patients with 
preserved EF and coronary artery disease, we tried to further 
investigate possible triggers of sFlt-1 release using animal 
models. In comparison with control group animals (n=4; mean 
sFlt-1=259.3 pg/mL), the MI animal models of HF showed sig-
nificant elevation in sFlt-1 levels after 4 and 8 weeks of LAD 
artery ligation (Figure 3). Similar findings were found as well 
in TAC models on 4 and 8 weeks after model design (Figure 3).
Discussion
There are several key observations. First, we demonstrate that 
patients with HF have significantly higher circulating sFlt-1 
and PlGF levels in comparison with normal healthy popula-
tion and regardless of impaired or preserved left ventricular 
EF. Increased levels of sFlt-1 were found to be associated with 
worse renal function, although they still independently pre-
dicted poor long-term survival. Using different forms of cardiac 
insult in animal models, we further demonstrated that elevated 
sFlt-1 levels occur irrespective of the types of inciting cardiac 
insults. Taken together, these observations imply that in patients 
with stable HF, high sFlt-1 may be generated as a consequence 
of the development and progression of HF. This may, in turn, 
reflect the critical role of imbalance in myocardial angiogenesis 
and the ventricular-arterial relationship in patients with HF.
Vascular markers were mainly studied in a preeclampsia 
population where low/high levels of PlGF/sFlt-1, respectively, 
were found to be associated with diffuse endothelial dysfunc-
tion and vascular rarefaction.1,3,4,7–9 Subsequently, protein urea, 
increased blood pressure, and eclampsia could develop.10 High 
sFlt-1 was also found to be associated with increased risk of 
peripartum cardiomyopathy.1,7 Similarly, administration of 
sFlt-1 in VEGF receptor depleted animals resulted in profound 
dilated cardiomyopathy with significant decreased in capillary 
density.1 However, intramyocardial provision of exogenous 
VEGF in animal models for pressure overload (aortic banding) 
has been shown to preserve coronary blood flow reserve and left 
ventricular performance.11–13 However, there are limited reports 
regarding the role of vascular markers in the pathogenesis and 
disease progression of HF. Both PlGF and sFlt-1 were found to 
be elevated after MI. High levels of PlGF were more in favor 
of myocardial recovery, whereas high sFlt-1 levels were associ-
ated with increased risk of myocardial dysfunction.1,2,14–16 The 
beneficial effect of exogenous PlGF in animal models post-MI 
was neutralized by administration of sFlt-1.2 Similarly, use of 
mimics to sFlt-1 (VEGF antagonists)-like bevacizumab was 
found to be associated with increased risk of HF develop-
ment.5,17 The prognostic value of circulating levels of vascular 
markers has previously been reported in HF with impaired EF 
(and largely nonischemic) patient population.4 In our observa-
tions from 2 separate cohorts, we have confirmed the associa-
tion with adverse outcomes. Although, our subgroup analyses 
revealed this association to be mainly driven by those with pre-
served EF and coronary artery disease, we did not find signifi-
cant interaction between sFlt-1 and EF. Furthermore, sFlt-1 was 
associated with adverse outcomes in TACC population (mainly 
nonischemic HF with low EF). Taken together, with our animal 
model findings, these results suggest the adverse association of 
sFlt-1 and HF is independent of the insulting factor.
Interestingly, high levels of PlGF in our population also 
showed unfavorable association with adverse outcomes. 
Table 1. Baseline Characteristics Stratified By sFlt-1 Levels
Total (n=791) sFlt-1<280 pg/mL (n=210) sFlt-1≥280 pg/mL (n=581) P Value
Age, y 66±11 67±10 66±11 0.805
Male, % 60 63 58 0.238
Black, % 4 2 5 0.139
Former/current smokers, % 70 72 69 0.548
Diabetes mellitus, % 41 45 40 0.294
Systolic blood pressure, mm Hg 128 (115–143) 132 (119–148) 127 (114–142) 0.011
Body mass index, kg/m2 28 (25–32) 29 (25–32) 28 (25–33) 0.593
Creatinine clearance, mL/min/1.73 m2 82.1 (60–109) 85 (66–113) 81 (58–109) 0.03
LDL cholesterol, mg/dL 92 (73–113) 92 (78–116) 91 (71–112) 0.156
HDL cholesterol, mg/dL 31 (26–39) 32 (27–39) 31 (26–40) 0.197
Coronary artery disease, % 76 81 75 0.117
Myocardial infarction, % 58 63 56 0.098
Atrial fibrillation, % 51 42 54 0.004
β-Blocker, % 67 71 66 0.145
ACE inhibitors or ARBs, % 68 73 66 0.039
Nitrates, % 39 41 39 0.542
ICD, % 10 8 11 0.258
CRT, % 1 0 1 0.087
B-type natriuretic peptide, pg/mL 298 (119–647) 183 (84–424) 342 (147–792) 0.001
Left ventricular ejection fraction, % 40 (25–55) 40 (30–55) 40 (25–55) 0.937
PlGF, pg/mL 24 (20–29) 23 (19–26) 25 (21–31) <0.001
sFlt-1, pg/mL 382 (277–953) 241 (223–262) 588 (359–1459) <0.001
Cardiac troponin I, ng/mL 0.009 (0.001–0.029) 0.007 (0–0.018) 0.011 (0.001–0.038) 0.003
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blockers; CRT, cardiac resynchronization therapy; HDL, high-density lipoprotein; ICD, 
implantable cardioverter defibrillator; LDL, low-density lipoprotein; PlGF, placental-like growth factor; and sFlt-1, soluble Fms-like tyrosine kinase-1.
Similar findings were suggested before in Ky et al4 study. 
Nakamura et al18 also found increased PlGF levels in patients 
with increased HF severity in ischemic cardiomyopathy. In 
contrary, reports from post-MI survivors showed favorable 
cardiac recovery in those with high PlGF.2,15 This may suggest 
protective role of PlGF in HF setting, and association with 
adverse outcome might be related to increase cardiac severity 
with a compensatory effort of the hypoxic tissue to overcome 
the on-going microvascular ischemia. The beneficial effect of 
PlGF/VEGF may be blocked and attenuated by high sFlt-1 
Figure 1. Plasma levels of placental-like growth factor (PlGF, A) and soluble Fms-like tyrosine kinase-1 (sFlt-1, B) in patients with heart 
failure (HF) stratified by impaired versus preserved left ventricular ejection fraction (LVEF) versus non-HF controls. Distribution of PlGF  
(C) and sFlt-1 (D) in HF and non-HF population.
Table 2. Long-Term Mortality Using Vascular Markers
Soluble Fms-Like Tyrosine Kinase-1 Placental-Like Growth Factor
<280 pg/mL (n=210) ≥280 pg/mL (n=581) P Value <25 pg/mL (n=442) ≥25 pg/mL (n=349) P Value
5-y death,* % 44/210=21.0% 184/581=31.7% 0.003 100/442=22.6% 128/349=36.7% <0.001
Unadjusted HR 1 1.67 (1.21–2.31) 0.002 1 1.77 (1.36–2.30) <0.001
Adjusted HR (model 1) 1 1.70 (1.20–2.41) 0.003 1 1.35 (1.00–1.81) 0.049
Adjusted HR (model 2) 1 1.48 (1.04–2.11) 0.029 1 1.29 (0.96–1.73) 0.093
Adjusted HR (model 3) 1 1.47 (1.03–2.09) 0.035 1 1.26 (0.94–1.71) 0.124
Model 1: adjusted for age, sex, race, logged body mass index, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log-
transformed creatinine clearance, diabetes mellitus, smoking, coronary artery disease, ACE inhibitors/ARBs, β-blockers, and log-transformed left ventricular ejection 
fraction. Model 2: adjusted for model 1 plus B-type natriuretic peptide. Model 3: adjusted for model 2 plus cardiac troponin I. HR indicates hazard ratio.
*Kaplan–Meier percentages.
levels and other comorbidities that attenuate neovascular 
response (eg, advance age, diabetes mellitus, increased oxida-
tive stress, and hypertension).19
Despite we found that levels of sFlt-1 and PlGF are higher 
in patients with HF compared with a normal healthy popu-
lation, it is worth noting that the concentrations of vascular 
markers are much lower than those reported during normal 
pregnancy and in preeclampsia.20 In comparison with preg-
nancy where the placenta is the major trigger of the vascular 
marker production,21 it is still unclear what the trigger is for 
circulating sFlt-1 and PlGF production in the setting of HF. 
Flt-1 is normally expressed on endothelial cells, and whether 
cleavage of this receptor is done by an enzyme, ischemia, 
or other stressors remains unclear. In our animal HF mod-
els, significant elevation in sFlt-1 was observed after both 
the LAD ligation and TAC models, which suggests vascu-
lar stress, myocardial ischemia, or even sympathetic drive 
may be possible triggers of sFlt-1 elevation. Indeed, previ-
ous reports found increased levels of sFlt-1 after MI.14–16 
Furthermore, increased levels of sFlt-1 were found in patients 
with resistant hypertension, and they were found to be associ-
ated with responders to renal denervation.22 These findings 
together with our observation in animal models suggest that 
any endothelial stressor may trigger increase sFlt-1 produc-
tion and release.
Study Limitations
Despite being one of the largest HF cohorts reported with 
vascular marker levels and long-term outcomes, our study has 
some limitations. First, we do not have complete data about 
cause of death, hospitalization, or consistent echocardio-
graphic indices (like left ventricular hypertrophy or diastolic 
indices) in all subjects. Second, we studied vascular mark-
ers at a single time point, and changes of vascular markers 
or treatment responses need to be further explored. Third, the 
Genebank study enrolled patients between 2001 and 2007, yet 
new HF treatment modalities, like biventricular pacing and 
aldosterone antagonist, were not commonly used. Whether 
these treatment modalities have any effect on the association 
between vascular markers and HF outcomes need to be further 
investigated.
Conclusion
sFlt-1 may be released as a result of myocardial injury and 
subsequent HF development. In high levels, sFlt-1 is associ-
ated with adverse outcomes in stable HF patients.
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